US President Donald Trump has announced reforms intended to speed up access to medical research and treatment based on psychedelic drugs.
Trump signed an executive order on Saturday that directs the US Food and Drug Administration to expedite review of drugs such as ibogaine, a drug that US military veteran groups have said can help treat post-traumatic stress disorder.
At an event in the Oval Office, US federal officials said that the reforms would pave the way for the drugs, which can cause hallucinations and are largely illegal, to be reclassified after successful clinical trials.
.@joerogan says he sent @POTUS information on the extraordinary effects of ibogaine on veterans with TBI and PTSD: “The text message came back, ‘Sounds great! Do you want FDA approval? Let’s do it!’ It was literally that quick.” https://t.co/Yw1NEAvmvz pic.twitter.com/Km3FITfE4p— Rapid Response 47 (@RapidResponse47) April 18, 2026
Trump also said the US would dedicate $US50 million ($A70 million) to federal research into ibogaine.
Lifeline 13 11 14
beyondblue 1300 22 4636
